Indapta Therapeutics Inc. has gained IND clearance from the FDA to commence a first-in-human phase I trial of IDP-023, an allogeneic natural killer (NK) cell therapy, in patients with relapsed or refractory multiple myeloma and lymphoma, anticipated to begin in the second half of this year. The study will explore three different dose levels of Indapta’s G-NK cells alone and in combination with IL-2 and the monoclonal antibodies rituximab and daratumumab.
Imaginab Inc. has selected and advanced into IND-enabling studies IAB-56, a minibody designed to target the αvβ6 integrin for use as Lu-177 radiopharmaceutical therapy in solid tumors. In parallel, the DLL3-targeting program, IAB-57, will further assess several leads in the coming quarter prior to initiation of IND-enabling studies later this year.
Although advances in chemotherapy have dramatically improved outcomes for children with leukemia, patients with high-risk and aggressive cancers require intense drug regimens that push safety limits. Researchers have formulated an antibody guidance system in mice that could empower chemotherapy against childhood leukemias while minimizing drug toxicity.
Impact Therapeutics (Shanghai) Inc. has identified substituted triazoloheteroaryl compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Monte Rosa Therapeutics Inc. has synthesized molecular glue degraders acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) and cereblon (CRBN) interaction inducers for GSPT1 degradation reported to be useful for the treatment of cancer.
Previous research demonstrated that the formation of PTEN-null tumors usually depends on the p100β catalytic isoform of PI3K (PI3Kβ); however, the mechanisms behind this dependency are unknown. In a recently published study, researchers from Dana-Farber Cancer Institute aimed to assess the role of PI3Kβ in immune evasion in PTEN-null breast cancer.
Transcription factor SP1 is a member of the Kruppel-like factor that has been shown to be overexpressed in several cancer types, including cervical cancer, and is associated with poor prognosis when overexpressed; assessing the impact of SP1 on tumor progression in cervical cancer was the aim of a recently published study by Wenzhou Medical University investigators.
Researchers from Nanjing University of Traditional Chinese Medicine reported the discovery and preclinical characterization of fluorine-substituted selective estrogen receptor degraders (SERDs) as potential candidates for the treatment of estrogen receptor (ER)-positive breast cancer.
Trueline Therapeutics Inc., a subsidiary of Anji Pharmaceuticals Inc., has successfully completed IND-enabling studies with Mcl-1 inhibitor TTX-810, a highly potent and selective macrocyclic compound to treat patients with solid tumor or hematological cancers. The company is now on track to initiate clinical development.
RSS
